



Commercial launch of dorsaVi's ViMove2™ to accelerate clinical market adoption

Key points:

- New dorsaVi Mini Sensors and app-based software platform for clinicians
- New patient app, myViMove, to engage patients, facilitate information sharing, distribute exercise programs and out-of-clinic movement monitoring
- Functionality and features optimised in line with market feedback
- Significantly reduced cost of goods and attractive entry price to build mass market opportunity

Melbourne, Australia – 15 May 2017: dorsaVi Ltd (ASX: DVL) today announces the commercial release of ViMove2™ in Australia representing an important next stage of the company's development.

ViMove2™ features smaller, faster and easier to use sensors, together with a simplified software interface, improved reporting tools, out of clinic monitoring, comprehensive exercise video library, and a patient app.

The patient app, myViMove, delivers assessment reports, customised exercise programs and data collection for out of clinic monitoring and is designed to engage patients in their treatments.

The ViMove2™ movement sensors are around a third of the size of the original ViMove sensors which dorsaVi launched in 2012. In addition to being significantly smaller, they are easy and quick to use for time-conscious clinicians. Three modules – Low Back, Knee and Run are included in the initial release. Further modules will be released over the next 12 months.



With a substantially reduced cost of goods, ViMove2™ will have a lower entry sale price will allow dorsaVi to build a critical mass of devices in market.

ViMove2™ has been developed as an ongoing annuity revenue product, replacing the model of outright unit sale or short-term lease originally launched for ViMove. The annuity model has been tested in the US clinical market over the past 12 months and has been successful in facilitating sales and providing a steady revenue stream.

ViMove2™ will be launched in Australia first and will be followed by the UK and the US markets. In Australia, the focus will be on building clinical adoption and particularly with physiotherapists, chiropractors, osteopaths and exercise physiologists. ViMove2™ will be sold through dorsaVi's direct sales team, third party referral networks, and online.

dorsaVi Chief Executive Officer Andrew Ronchi said: “This new product brings together new technology and significant insights from the clinical market.”

“ViMove2™ is highly intuitive, simple and a faster to use device with the addition of a patient app, allowing patients and therapists to continue to monitor progress and improve adherence to treatment regimes.”

Watch the ViMove2™ overview video: <http://get.dorsavi.com/vimove2/> .

ends

For more information or to arrange an interview, contact:

MEDIA

Megan Connell

dorsaVi

0416 116 526

mconnell@dorsavi.com

INVESTOR

Rebecca Wilson

Buchan Consulting

0417 382 391

rwilson@buchanwe.com.au

About dorsaVi

dorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** ViMove is transforming the management of patients by providing an objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia, United Kingdom and the United States.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs and the Australian Institute of Sport (AIS) in Australia. In the UK, Barclays Premier League (EPL), U.S. based sports clubs including the National Basketball Association (NBA) and the National Football League (NFL), and various Olympic teams and athletes internationally.
- **OHS:** We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.

Further information is available at www.dorsavi.com.